Since April 1st 2017 the non-invasive prenatal test (NIPT) is available for every pregnant woman in the Netherlands. The NIPT is considered a more accurate screening test for down-, edwards- and patausyndrome than the first trimester combined test (FTS). The test is based on the analysis of fetal DNA, obtained from maternal blood. The NIPT is less invasive than other prenatal tests and there are no risks for the unborn child.
In the Netherlands, before Aprilthe NIPT was only available for women at elevated risk of having a fetus with down-, edwards-, or patausyndrome, previously determined by the first trimester combined test (FTC). From April onward till April 2020, the NIPT is available for every Dutch pregnant woman within the TRIDENT-2 study (Trial by Dutch laboratories for Evaluation of Non-invasive Prenatal Testing). Due to a subsidy of the Ministry of Health, Welfare and Sports the NIPT has the same price as the first trimester combined test. Women who want to have prenatal screening can now choose which test they prefer (NIPT or FCT).
The NIPT consortium, in which the Dutch UMC’s among others cooperate with professional organizations Koninklijke Nederlandse Organisatie van Verloskundigen (KNOV), Nederlandse Verening voor Obstetrie en Gynaecologie (NVOG), Vereniging Klinische Genetica Nederland (VKGN) and Vereniging Klinische Genetische Laboratoriumdiagnostiek (VKGL) and the Dutch Genetic Alliance (VSOP), proposed the TRIDENT study and applied for the license at the Minister of Health. APH researcher Dr Lidewij Henneman (VUmc Department of Clinical Genetics, section Community Genetics) is project coordinator of the TRIDENT-2 study on the part studying women’s perspectives, that recently received a 350.000 ZonMw grant.
NIPT in the news (Source: NPO)
Read more about the NIPT:
Read about the NIPT in the media: